Pantoprazole With Doxorubicin for Advanced Cancer Patients With Extension Cohort of Patients With Solid Tumours
Status:
Completed
Trial end date:
2015-05-01
Target enrollment:
Participant gender:
Summary
This is a single-centre, open label, dose finding, phase I study to determine the recommended
phase II dose (RP2D) for the combination of doxorubicin and pantoprazole in patients with
advanced tumours and no standard treatment options. A minimum of 3 patients will be enrolled
per dose level and intra-patient dose escalation is not permitted. Once the RP2D has been
identified, six additional patients with metastatic solid tumours will be treated at the RP2D
to confirm its tolerability.